Norway· NO-ID_5C79D0B6-9C4A-4D66-ABBF-7C16A1787586
Xospata
A gilteritinib product containing gilteritinib, registered in Norway by Astellas Pharma Europe B.V. - Leiden. The same ATC class is registered in 13 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Gilteritinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EX13 (gilteritinib), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Gilteritinib · ATC L01EX13
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of gilteritinib costs, country by country.
Normalised to the WHO defined daily dose (0.12 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Gilteritinib · price per daily dose (0.12 g)
USD · FX 28 Sept 2026
- CH Switzerland$662.17
The record
At a glance
FEST (Norway)- Active substance
- Gilteritinib
- Manufacturer
- Astellas Pharma Europe B.V. - Leiden
- Country
- Norway (NO)
- ATC code
- L01EX13
- ATC class
- Gilteritinib
- Defined daily dose
- 0.12 g, O
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_varenummer08230984NOK 224644.2
- gtin5703483100841
- no_merkevare_idID_5C79D0B6-9C4A-4D66-ABBF-7C16A1787586
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
529 interactions on record for gilteritinib.
Graded by severity as the source publishes them — 116 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Gilteritinib · interactions on record
529 records
- 116 severe
- 408 moderate
- 5 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- LonafarnibA16AX20severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Gilteritinib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumXospata 40 mgAstellas Pharma Europe
- SwitzerlandXospata 40 mg, FilmtablettenAstellas Pharma AG
- CzechiaXOSPATAAstellas Pharma Europe B.V., Leiden
- SpainXOSPATA 40 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAstellas Pharma Europe B.V.
- FinlandXospataAstellas Pharma Europe B.V.
- FranceXOSPATA 40 mg, comprimé pelliculéASTELLAS PHARMA EUROPE (PAYS-BAS)
- IrelandXospata 40 mg film-coated tabletsAstellas Pharma Europe B.V.
- NetherlandsXospata 40 mg, filmomhulde tablettenAstellas Pharma Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Xospata
- Liechtenstein · Xospata
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0dfbbc29-b841-4da4-b152-1297afe03eff GET /v1/drugs/0dfbbc29-b841-4da4-b152-1297afe03eff?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablett, filmdrasjert",
"source": "fest",
"status": "A",
"atc_name": "Gilteritinib",
"merkevare_id": "ID_5C79D0B6-9C4A-4D66-ABBF-7C16A1787586",
"name_form_strength": "Xospata tab 40 mg",
"prescription_group": "C"
}See everything about gilteritinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.